Benzinga · Jul 21, 2026
Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $59 to $67.
NASDAQ · ELVN
Enliven Therapeutics, Inc.
Healthcare · Biotechnology
$44.25
Down-$0.83 (-1.84%)
Updated Oct 31, 2026, 2:48 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.11B
- P/E ratio
- -9.76
- Dividend yield
- 0.00%
- 52-week range
- $26.70 – $62.32
- Volume
- 1.24M
- Avg. volume
- 581.23K
Price performance · ELVN
ELVN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ELVN closed at $44.25 after 21 trading sessions, down 5.79% for the selected period.
- Last close
- $44.25
- Period change
- -5.79%
- Period low
- $37.32
- Period high
- $46.97
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $44.92 | $45.87 | $44.09 | $44.25 | 1.24M |
| Oct 29, 2026 | $45.29 | $45.72 | $44.44 | $45.08 | 909.46K |
| Oct 28, 2026 | $43.69 | $44.94 | $43.39 | $44.78 | 1.26M |
| Oct 27, 2026 | $41.80 | $44.37 | $41.52 | $43.69 | 3.31M |
| Oct 26, 2026 | $41.58 | $42.175 | $40.90 | $41.49 | 2.32M |
| Oct 23, 2026 | $41.49 | $41.64 | $40.82 | $41.52 | 2.3M |
| Oct 22, 2026 | $41.55 | $42.87 | $41.0596 | $41.93 | 2.32M |
| Oct 21, 2026 | $41.76 | $42.92 | $41.585 | $41.82 | 2.05M |
| Oct 20, 2026 | $38.86 | $41.365 | $38.41 | $41.25 | 1.94M |
| Oct 19, 2026 | $38.01 | $38.8267 | $37.50 | $38.70 | 1.31M |
| Oct 16, 2026 | $39.33 | $39.465 | $36.955 | $37.32 | 1.19M |
| Oct 15, 2026 | $39.48 | $40.29 | $38.49 | $39.33 | 2.05M |
| Oct 14, 2026 | $38.99 | $39.95 | $38.51 | $39.28 | 1.22M |
| Oct 13, 2026 | $40.56 | $40.99 | $39.27 | $39.49 | 847.88K |
| Oct 12, 2026 | $40.67 | $41.41 | $40.50 | $40.84 | 579.82K |
| Oct 9, 2026 | $41.00 | $42.06 | $40.29 | $40.98 | 1M |
| Oct 8, 2026 | $40.90 | $40.90 | $39.25 | $40.63 | 1.65M |
| Oct 7, 2026 | $41.62 | $42.38 | $41.04 | $41.36 | 1.46M |
| Oct 6, 2026 | $45.38 | $45.605 | $41.22 | $42.39 | 2.33M |
| Oct 5, 2026 | $46.94 | $46.94 | $45.2301 | $45.47 | 821.51K |
| Oct 2, 2026 | $47.38 | $47.43 | $45.92 | $46.97 | 1.12M |
Latest ELVN news
The latest Smart Investors Daily articles mentioning ELVN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ELVN research
Overview
Company profile and research snapshot.
Company profile
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $52.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 2, 2026 | Morgan Stanley | Overweight | — |
| Oct 1, 2026 | JP Morgan | Overweight | — |
| Aug 18, 2026 | William Blair | Outperform | — |
| Aug 18, 2026 | Barclays | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 1, 2026
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
The Chief Scientific Officer of this biopharmaceutical company sold 20,000 shares in mid-January 2026, amid the company's stock rising 71% throughout the month.
SeekingAlpha · Jan 13, 2026
Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious
Enliven Therapeutics (ELVN) jumped on strong ELVN-001 phase 1b CML data, but a rich valuation may cap upsideâget the latest analysis now. Click here to read.
prnewswire.com · Dec 11, 2025
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that on December 11, 2025, Enliven granted an inducement stock option to purchase 875,000 shares of Enliven's common stock to Richard Fair, Enliven's President and Chief Executive Officer and member of the board of directors, in connection with the commencement of Richard Fair's employment.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
